PSC
VYNE icon

Piper Sandler & Co’s VYNE Therapeutics VYNE Stock Holding History

Piper Sandler & Co’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Hold
0
– – – 17
2018
Q4 		– Sell
-12
Closed -$5.37K – 17
2018
Q3 		$9K Buy
+12
New +$7.41K 0.01% 14

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Piper Sandler & Co's VYNE Position: Q1 2019 in Review

Piper Sandler & Co held its VYNE Therapeutics (VYNE) position steady in Q1 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #17.

Piper Sandler & Co first reported a position in VYNE in Q3 2018 and has held it in 1 quarter since. The position peaked at $9K in Q3 2018. 59 funds tracked by Wall St. Rank hold VYNE as of Q1 2019.

  • Piper Sandler & Co held 0 shares of VYNE Therapeutics worth $0 as of Q1 2019.
  • Piper Sandler & Co left its VYNE Therapeutics share count unchanged in Q1 2019.
  • VYNE Therapeutics made up ﹤0.01% of Piper Sandler & Co's portfolio in Q1 2019, its #17 holding.
  • Piper Sandler & Co first reported a position in VYNE Therapeutics in Q3 2018 and has held it in 1 quarter since.
  • Piper Sandler & Co's VYNE Therapeutics position peaked at $9K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2019.

Based on Piper Sandler & Co's 13F filing for Q1 2019, filed 15 May 2019.